stockrow
Saturday 7 November 2026
Export SLS’s income statement to Excel — free account
SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.0 million.
- EPS
- +28.6%
- Free cash flow
- −3.52%
Quarter to June 2026, against a year earlier
8.29
0.41
+5.20%
Follow SLS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 2 | 8 | 1 | — | — | — | 11 | (27.5%) | — | 53 | 122 | +129.8% | |
| Gross margin, % | 0.00 | — | — | — | 100.00 | 97.37 | 90.00 | — | — | — | 0.00 | +90.0 pt | ||||||
| EBT | (18) | (24) | (29) | (19) | (17) | (21) | (41) | (37) | (31) | (27) | (32) | +4.8% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | (882.84) | (275.47) | (4,130.10) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (18) | (24) | (28) | (19) | (17) | (21) | (41) | (37) | (31) | (27) | (32) | +4.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 0.49 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (933.53) | (522.00) | (157.50) | (10.92) | (2.11) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) | (0.21) | (59.9%) | ||||||
| Cash flow | (626.98) | (234.81) | (116.11) | (6.89) | (1.31) | (1.68) | (1.23) | (1.13) | (0.58) | (0.26) | (0.15) | (57.9%) | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.46) | (0.20) | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (626.98) | (234.81) | (116.11) | (6.89) | (1.31) | (1.68) | (1.69) | (1.33) | (0.58) | (0.26) | (0.15) | (57.9%) | ||||||
| Book value | (264.39) | 44.23 | 20.02 | 2.38 | 3.51 | 1.31 | 0.25 | (0.29) | 0.15 | 0.65 | 0.73 | n/m | ||||||
| Shares, m | 0 | 0 | 0 | 3 | 8 | 15 | 19 | 28 | 61 | 109 | 145 | +161.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 6.12 | 7.24 | 4.71 | — | — | — | 149.37 | 6.0 | ||||||
| P/B | — | — | — | — | 1.66 | 4.21 | 10.20 | — | — | — | 11.39 | 5.4 | ||||||
| EV/Sales | — | — | — | — | 1.56 | 5.48 | 3.11 | — | — | — | 136.22 | 3.4 | ||||||
| EV/FCF | — | — | — | — | (1.13) | (2.48) | (1.15) | — | — | — | (37.22) | (1.6) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (12) | (11) | (30) | (18) | (10) | (26) | (24) | (31) | (35) | (28) | (28) | +10.2% | |||||
| Capex | — | — | — | — | — | — | (9) | (5) | 0 | — | (5) | n/m | ||||||
| Free cash flow | (12) | (11) | (30) | (18) | (10) | (26) | (33) | (37) | (35) | (28) | (28) | +10.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 1 | (11) | 0 | 3 | 25 | 18 | 2 | (11) | 7 | 68 | 135 | +68.6% | |||||
| Net debt | 1 | (2) | (5) | (7) | (35) | (21) | (17) | (3) | (14) | (72) | (138) | n/m | ||||||
| Shareholders’ equity | (5) | 2 | 5 | 6 | 28 | 20 | 5 | (8) | 9 | 71 | 138 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (39.93) | (122.31) | (163.56) | (166.75) | (53.74) | (57.24) | (174.94) | (274.94) | (240.78) | (54.95) | (36.54) | (15.0) pt | |||||
| ROIC | 0.00 | (4,675.12) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (415.24) | 1,669.22 | (1,127.85) | (493.05) | (98.87) | (85.70) | (327.81) | 2,389.76 | (4,147.88) | (66.88) | (39.63) | +348.4 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 14 | 9 | 9 | 5 | 7 | 11 | 17 | 16 | 15 | 13 | — | (0.8%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.27 | 0.69 | 0.06 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2022 · latest quarter Mar 2022
SELLAS Life Sciences Group, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics, Inc. | $1.6B | 6.1× | 5.5× | +8,426.27% (above 0%: growing) | n/m | +1,122.10% (above 0%: growing) | 100.00% | 83.12% | Compare |
| ABSI Absci Corporation | $1.6B | — (loss-making) | — (loss-making) | −46.37% (below 0%: shrinking) | n/m | −71.74% (below 0%: shrinking) | 100.00% | (10,741.51%) | Compare |
| GENB Generate Biomedicines, Inc. | $1.6B | — (loss-making) | — (loss-making) | — | n/m | −224.24% (below 0%: shrinking) | 100.00% | (1,134.21%) | Compare |
| NVAX Novavax, Inc. | $1.6B | — (loss-making) | 110× | −3.05% (below 0%: shrinking) | n/m | −189.09% (below 0%: shrinking) | 65.61% | (45.80%) | Compare |
| SLS SELLAS Life Sciences Group, Inc. | $1.6B | — (loss-making) | — (loss-making) | −57.10% (below 0%: shrinking) | n/m | −3.52% (below 0%: shrinking) | 0.00% | 0.00% | |
| KLRA Kailera Therapeutics, Inc. | $1.6B | — (loss-making) | — | — | n/m | −325.95% (below 0%: shrinking) | — | 0.00% | Compare |
| BRVE Braveheart Bio, Inc. | $1.6B | — | — | — | n/m | — | — | 0.00% | Compare |
| NTLA Intellia Therapeutics, Inc. | $1.6B | — (loss-making) | — (loss-making) | −48.03% (below 0%: shrinking) | n/m | −11.05% (below 0%: shrinking) | 100.00% | (1,707.73%) | Compare |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | — (loss-making) | — (loss-making) | +8.13% (above 0%: growing) | n/m | +12.50% (above 0%: growing) | 81.50% | (63.58%) | Compare |
| Median of peers | $1.6B | — | — | −3.05% | — | −71.74% | 100.00% | (54.69%) |
Pay and ownership Proxy statement filed 23 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.88m | 4.43m | 159.75 |
| 2024 | 1.19m | 1.33m | 44.07 |
| 2023 | 1.75m | 801.28k | 44.92 |
Ownership
Directors and executive officers, together
1.30%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement